Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AML

Jeffrey Lancet, MD
Published: Friday, Feb 24, 2017



Jeffrey Lancet, MD, of Moffitt Cancer Center, explains the use of CPX-351 compared with induction chemotherapy for older adult patients with acute myeloid leukemia (AML).

More patients with AML were able to proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen, Lancet notes. As such, Lancet believes that CPX-351 could serve as a potential bridge to successful allogeneic transplant.

Data from the phase III study showed that 65% of patients in the CPX-351 arm who proceeded to transplant survived, at a follow-up of 521 days. In the standard of care arm, 33% of patients survived at a 442-day follow-up. 

<<< View more from the 2017 BMT Tandem Meetings


Jeffrey Lancet, MD, of Moffitt Cancer Center, explains the use of CPX-351 compared with induction chemotherapy for older adult patients with acute myeloid leukemia (AML).

More patients with AML were able to proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen, Lancet notes. As such, Lancet believes that CPX-351 could serve as a potential bridge to successful allogeneic transplant.

Data from the phase III study showed that 65% of patients in the CPX-351 arm who proceeded to transplant survived, at a follow-up of 521 days. In the standard of care arm, 33% of patients survived at a 442-day follow-up. 

<<< View more from the 2017 BMT Tandem Meetings

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x